StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Strategic Oncology Affiliate by Year

Strategic Oncology Affiliate — Arcus Biosciences (NYSE: RCUS) Total Revenues ($M) ($M)

QuarterlyAnnual

Gilead Sciences Strategic Oncology Affiliate: $33M in FY2025, down 35.3% from a year earlier.

Latest, FY2025
33
Period ended Dec 31, 2025
Change on a year earlier
-35.3%
51 in FY2024
History
7 years
Since FY2019
Sources
5
Documents cited below

Where the FY2025 figure comes from

Source: Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗

Reported in Arcus Biosciences, Inc. (NYSE: RCUS, CIK 0001724521) Form 10-Q / 10-K.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedStrategic Oncology Affiliate — Arcus Biosciences (NYSE: RCUS) Total Revenues ($M) ($M)Year on yearSource
FY2025Dec 31, 202533-35.3%Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗
FY2024Dec 31, 202451+37.8%Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗
FY2023Dec 31, 202337-2.6%Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗
FY2022Dec 31, 202238-90.1%Arcus Biosciences (RCUS) Form 10-K (filed 2025-02-25) ↗
FY2021Dec 31, 2021383+391.0%Arcus Biosciences (RCUS) Form 10-K (filed 2024-02-21) ↗
FY2020Dec 31, 202078+420.0%SEC Filing ↗
FY2019Dec 31, 201915–SEC Filing ↗

Breakdown

What makes up strategic Oncology Affiliate

Cite this data

StockData. (2026). Gilead Sciences Strategic Oncology Affiliate ($M), annual FY2019–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus-rev-tot

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.